sibmedСибирский научный медицинский журналСибирский научный медицинский журнал2410-25122410-2520ИЦиГ СО РАН10.18699/SSMJ20250303sibmed-2228Research ArticleОБЗОРЫREVIEWSПерспективы применения флавоноидов при остеопорозеProspects for the use of flavonoids in osteoporosishttps://orcid.org/0000-0002-8101-103XЗверевЯ. Ф.ZverevYa. F.

Яков Федорович Зверев, д. м. н., проф.

656038; пр. Ленина, 40; Барнаул

Yakov F. Zverev, doctor of medical science, professor

656038; Lenina ave., 40; Barnaul

zveryasha@mail.ruhttps://orcid.org/0000-0002-5889-7071РыкуноваА. Я.RykunovaA. Ya.

Анна Яковлевна Рыкунова, к. м. н.

656038; пр. Ленина, 40; Барнаул

Anna Ya. Rykunova, candidate of medical sciences

656038; Lenina ave., 40; Barnaul

zveranna@mail.ruАлтайский государственный медицинский университет Минздрава РоссииРоссияAltai State Medical University of Minzdrav of RussiaRussian Federation2025130720254532642Copyright © Зверев Я.Ф., Рыкунова А.Я., 20252025Зверев Я.Ф., Рыкунова А.Я.Zverev Y.F., Rykunova A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://sibmed.elpub.ru/jour/article/view/2228

   Обзор посвящен целесообразности применения флавоноидов в комплексной терапии остеопороза. Многочисленные виды фармакологической активности, присущие этим полифенольным соединениям растительного происхождения, в том числе противовоспалительная, антиоксидантная, антипролиферативная, иммуномодулирующая, противоопухолевая, антикоагулянтная и другие, заставили с вниманием подойти к возможности их клинической эффективности при костной патологии. Экспериментальные исследования последних лет позволили установить, что протективное действие флавоноидов, препятствующее патологической потере кости, обусловлено, прежде всего, активацией формирования новой костной ткани путем стимуляции пролиферации и дифференцировки остеобластов, а также ослаблением процесса резорбции кости за счет угнетения остеокластогенеза. Обсуждаются возможные механизмы отмеченных эффектов с учетом воздействия на процессы внутриклеточного сигнализирования. Отмечается положительное влияние на процесс остеогенеза эстрогеноподобных свойств ряда флавоноидов. В обзоре рассмотрены многообещающие свойства наиболее широко встречающихся флавонолов, флавонов, флаванонов, флаван-3-одов (катехинов), антоцианидинов, изофлавонов, позволяющие с оптимизмом смотреть на их клиническое применение в будущем. Как полагают многие авторы, дальнейшие углубленные доклинические исследования должны ответить на многие сохраняющиеся вопросы, касающиеся механизмов действия флавоноидов, а также решить проблему их биодоступности.

   The review is devoted to the feasibility of using flavonoids in the complex therapy of osteoporosis. Numerous types of pharmacological activity inherent in these polyphenolic compounds of plant origin, including anti-inflammatory, antioxidant, antiproliferative, immunomodulatory, antitumor, anticoagulant and others, forced us to carefully approach the possibility of their clinical effectiveness in bone pathology. Experimental studies of recent years have shown that the protective effect of flavonoids preventing pathological bone loss is primarily due to activation of new bone tissue formation by stimulating proliferation and differentiation of osteoblasts, as well as weakening the bone resorption process by inhibiting osteoclastogenesis. Possible mechanisms of the noted effects are discussed taking into account the impact on intracellular signaling processes. A positive effect of estrogen-like properties of a number of flavonoids on the osteogenesis process is noted. The review considers the promising properties of the most widely encountered flavonols, flavones, flavanones, flavan-3-ods (catechins), anthocyanidins, and isoflavones, allowing one to look with optimism at their clinical application in the future. As many authors believe, further in-depth preclinical studies should answer many remaining questions regarding the mechanisms of action of flavonoids, as well as solve the problem of their bioavailability.

остеопорозфлавоноидыостеобластогенезостеокластогенезмеханизмы действияоsteoporosisflavonoidsosteoblastogenesisosteoclastogenesismechanisms of actionReferencesНуруллина Г.М., Ахмадуллина Г.И. Костное ремоделирование в норме и при первичном остеопорозе: значение маркеров костного ремоделирования. Арх. внутр. мед. 2018;8(2):100–110. doi: 10.20514/2226-6704-2018-8-2-100-110Nurullina G.M., Akhmadullina G.I. Bone remodeling in norm and in primary osteoporosis: the significance of bone remodeling markers. Arkhiv vnutrenney meditsiny = Archive of Internal Medicine. 2018;8(2):100–110. [In Russian]. doi: 10.20514/2226-6704-2018-8-2-100-110Игнатенко Г.А., Немсадзе И.Г., Мирович Е.Д., Чурилов А.В., Майлян Э.А., Глазков И.С., Румянцева З.С. Роль цитокинов в ремоделировании костной ткани и патогенез постменопаузального остеопороза. Мед. вестн. Юга России. 2020;11(2):6–18. doi: 10.21886/2219-8075-2020-11-2-6-18Ignatenko G.A., Nemsadze I.G., Mirovich E.D., Churilov A.V., Maylyan E.A., Glazkov A.E., Rumyantceva Z.S. The role of cytokines in bone remodeling and the pathogenesis of postmenopausal osteoporosis. Meditsinskiy vestnik Yuga Rossii = Medical Herald of the South of Russia. 2020;11(2):6–18. [In Russian]. doi: 10.21886/2219-8075-2020-11-2-6-18Ялаев Б.И., Хусаинова P.И. Эпигенетическая регуляция ремоделирования костной ткани и ее роль в патогенезе первичного остеопороза. Вавил. ж. генетики и селекции. 2023;27(4):401–410. doi: 10.18699/VJGB-23-48Yalaev B.I., Khusainova R.I. Epigenetic regulation of bone remodeling and its role in the pathogenesis of primary osteoporosis. Vavilovskiy zhurnal genetiki i selektsii = Vavilov Journal of Genetics and Breeding. 2023;27(4):401–410. [In Russian]. doi: 10.18699/VJGB-23-48Kim J.M., Lin C., Stavre Z., Greenblatt M.B., Shim J.H. Osteoblast-osteoclast communications and bone homeostasis. Cells. 2020;9(19):2073. doi: 10.3390/cells9092073Kim J.M., Lin C., Stavre Z., Greenblatt M.B., Shim J.H. Osteoblast-osteoclast communications and bone homeostasis. Cells. 2020;9(19):2073. doi: 10.3390/cells9092073Yang R., Li J., Zhang J., Xue Q., Qin R., Wang R., Goltzman D., Miao D. 17β-estradiol plays the anti-osteoporosis role via a novel ESR1-Keap1-Nrf2 axismediated stress response activation and Tmem119 up-regulation. Free Radic. Biol. Med. 2023;195:231–244. doi: 10.1016/j.freeradbiomed.2022.12.102Yang R., Li J., Zhang J., Xue Q., Qin R., Wang R., Goltzman D., Miao D. 17β-estradiol plays the anti-osteoporosis role via a novel ESR1-Keap1-Nrf2 axismediated stress response activation and Tmem119 up-regulation. Free Radic. Biol. Med. 2023;195:231–244. doi: 10.1016/j.freeradbiomed.2022.12.102Li Q., Tian C., Liu X., Li D., Liu H. Anti-inflammatory and antioxidant traditional Chinese Medicine in treatment and prevention of osteoporosis. Front. Pharmacol. 2023;14:1203767. doi: 10.3389/fphar.2023.1203767Li Q., Tian C., Liu X., Li D., Liu H. Anti-inflammatory and antioxidant traditional Chinese Medicine in treatment and prevention of osteoporosis. Front. Pharmacol. 2023;14:1203767. doi: 10.3389/fphar.2023.1203767Gu Z., Zhou G., Zhang X., Liang G., Xiao X., Dou Y. Research progress of plant medicine and Chinese herbal compounds in the treatment of rheumatoid arthritis combined with osteoporosis. Front. Med. (Lausanne). 2024;10:1288591. doi: 10.3389/fmed.2023.1288591Gu Z., Zhou G., Zhang X., Liang G., Xiao X., Dou Y. Research progress of plant medicine and Chinese herbal compounds in the treatment of rheumatoid arthritis combined with osteoporosis. Front. Med. (Lausanne). 2024;10:1288591. doi: 10.3389/fmed.2023.1288591Zhou C., Shen S., Zhang M., Luo H., Zhang Y., Wu C., Zeng L., Ruan H. Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese Medicine for managing osteoporosis: a literature review. Front. Med. (Lausanne). 2023;10:1235081. doi: 10.3389/fmed.2023.1235081Zhou C., Shen S., Zhang M., Luo H., Zhang Y., Wu C., Zeng L., Ruan H. Mechanisms of action and synergetic formulas of plant-based natural compounds from traditional Chinese Medicine for managing osteoporosis: a literature review. Front. Med. (Lausanne). 2023;10:1235081. doi: 10.3389/fmed.2023.1235081Cao G., Hu S.Q., Ning Y., Dou X., Ding C., Wang L., Wang Z., Sang X., Yang Q., Shi J., Hao M., Han X. Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity. Front. Pharmacol. 2024;15:1370900. doi: 10.3389/fphar.2024.1370900Cao G., Hu S.Q., Ning Y., Dou X., Ding C., Wang L., Wang Z., Sang X., Yang Q., Shi J., Hao M., Han X. Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity. Front. Pharmacol. 2024;15:1370900. doi: 10.3389/fphar.2024.1370900Зверев Я.Ф., Рыкунова А.Я. Фармакология флавоноидов. Барнаул, 2023. 178 c. – Zverev Ya.F., Rykunova A.Ya. Pharmacology of flavonoids. Barnaul, 2023. 178 p. [In Russian].Зверев Я.Ф., Рыкунова А.Я. Фармакология флавоноидов. Барнаул, 2023. 178 c. – Zverev Ya.F., Rykunova A.Ya. Pharmacology of flavonoids. Barnaul, 2023. 178 p. [In Russian].Ramesh P., Jagadeesan R., Sekaran S., Dhanasekaran A., Vimalraj S. Flavonoids: classification, function, and molecular mechanisms involved in bone remodeling. Front. Endocrinol. (Lausanne). 2021;12:779638. doi: 10.3389/fendo.2021.779638Ramesh P., Jagadeesan R., Sekaran S., Dhanasekaran A., Vimalraj S. Flavonoids: classification, function, and molecular mechanisms involved in bone remodeling. Front. Endocrinol. (Lausanne). 2021;12:779638. doi: 10.3389/fendo.2021.779638Bellavia D., Dimarco E., Costa V., Carina V., de Luca A., Raimondi L., Fini M., Gentile C., Caradonna F., Giavaresi G. Flavonoids in bone erosive diseases: perspectives in osteoporosis treatments. Trends Endocrinol. Metab. 2021;32(2):76–94. doi: 10.1016/j.tem.2020.11.007Bellavia D., Dimarco E., Costa V., Carina V., de Luca A., Raimondi L., Fini M., Gentile C., Caradonna F., Giavaresi G. Flavonoids in bone erosive diseases: perspectives in osteoporosis treatments. Trends Endocrinol. Metab. 2021;32(2):76–94. doi: 10.1016/j.tem.2020.11.007Sharma A.R., Lee Y.H., Bat-Ulzii A., Chatterjee S., Bhattacharya M., Chakraborty C., Lee S.S. Bioactivity, molecular mechanism, and targeted delivery of flavonoids for bone loss. Nutrients. 2023;15(4):919. doi: 10.3390/nu15040919Sharma A.R., Lee Y.H., Bat-Ulzii A., Chatterjee S., Bhattacharya M., Chakraborty C., Lee S.S. Bioactivity, molecular mechanism, and targeted delivery of flavonoids for bone loss. Nutrients. 2023;15(4):919. doi: 10.3390/nu15040919Guan F., Wang Q., Bao T., Chao Y. Anti-rheumatic effect of quercetin and recent developments in nano formulation. RSC Adv. 2021;11(13):7280–7293. doi: 10.1039/d0ra08817jGuan F., Wang Q., Bao T., Chao Y. Anti-rheumatic effect of quercetin and recent developments in nano formulation. RSC Adv. 2021;11(13):7280–7293. doi: 10.1039/d0ra08817jTang M., Zeng Y., Peng W., Xie X., Yang Y., Ji B., Li F. Pharmacological aspects of natural quercetin in rheumatoid arthritis. Drug Des. Devel. Ther. 2022;16:2043–2053. doi: 10.2147/DDDT.S364759Tang M., Zeng Y., Peng W., Xie X., Yang Y., Ji B., Li F. Pharmacological aspects of natural quercetin in rheumatoid arthritis. Drug Des. Devel. Ther. 2022;16:2043–2053. doi: 10.2147/DDDT.S364759Loukas A.T., Papadourakis M., Panagiotopoulos V., Zarmpala A., Chontzopoulou E., Christodoulou S., Katsila T., Zoumpoulakis P., Matsoukas M.T. Natural compounds for bone remodeling: a computational and experimental approach targeting bone metabolism-related proteins. Int. J. Mol. Sci. 2024;25(9):5047. doi: 10.3390/ijms25095047Loukas A.T., Papadourakis M., Panagiotopoulos V., Zarmpala A., Chontzopoulou E., Christodoulou S., Katsila T., Zoumpoulakis P., Matsoukas M.T. Natural compounds for bone remodeling: a computational and experimental approach targeting bone metabolism-related proteins. Int. J. Mol. Sci. 2024;25(9):5047. doi: 10.3390/ijms25095047Wei Q., Ouyang M., GuoX., Fu X., Liu T., Luo Y., Tang H., Yang Y., Gao X., Mao H. Effect of hyperoside on osteoporosis in ovariectomized mice through estrogen receptor α/ITGβ3 signaling pathway. Eur. J. Pharmacol. 2024;977:176666. doi: 10.1016/j.ejphar.2024.176666Wei Q., Ouyang M., GuoX., Fu X., Liu T., Luo Y., Tang H., Yang Y., Gao X., Mao H. Effect of hyperoside on osteoporosis in ovariectomized mice through estrogen receptor α/ITGβ3 signaling pathway. Eur. J. Pharmacol. 2024;977:176666. doi: 10.1016/j.ejphar.2024.176666Pang X.G., Cong Y., Bao N.R., Li Y.G., Zhao J.N. Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway. Bio. Med. Res. Int. 2018;2018:4178021. doi: 10.1155/2018/4178021Pang X.G., Cong Y., Bao N.R., Li Y.G., Zhao J.N. Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway. Bio. Med. Res. Int. 2018;2018:4178021. doi: 10.1155/2018/4178021Zhao J., Wu J., Xu B., Yuan Z., Leng Y., Min J., Lan X., Luo J. Kaempferol promotes bone formation in part via the mTOR signaling pathway. Mol. Med. Rep. 2019;20(6):5197–5207. doi: 10.3892/mmr.2019.10747Zhao J., Wu J., Xu B., Yuan Z., Leng Y., Min J., Lan X., Luo J. Kaempferol promotes bone formation in part via the mTOR signaling pathway. Mol. Med. Rep. 2019;20(6):5197–5207. doi: 10.3892/mmr.2019.10747Liu H., Yi X., Tu S., Cheng C., Luo J. Kaempferol promotes BMSC osteogenic differentiation and improves osteoporosis by downregulation miR-10a-3p and upregulating CXCL12. Mol. Cell. Endocrinol. 2021;520:111074. doi: 10.1016/j.mce.2020.111074Liu H., Yi X., Tu S., Cheng C., Luo J. Kaempferol promotes BMSC osteogenic differentiation and improves osteoporosis by downregulation miR-10a-3p and upregulating CXCL12. Mol. Cell. Endocrinol. 2021;520:111074. doi: 10.1016/j.mce.2020.111074Nowak B., Matuszewska A., Nikodem A., Filipiak J., Landwójtowicz M., Sadanowicz E., Jędrzejuk D., Rzeszutko M., Zduniak K., Piasecki T., … Szelag A. Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia. Pharmacol. Rep. 2017;69(5):1113–1119. doi: 10.1016/j.pharep.2017.05.002Nowak B., Matuszewska A., Nikodem A., Filipiak J., Landwójtowicz M., Sadanowicz E., Jędrzejuk D., Rzeszutko M., Zduniak K., Piasecki T., … Szelag A. Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia. Pharmacol. Rep. 2017;69(5):1113–1119. doi: 10.1016/j.pharep.2017.05.002Lee C.J., Moon S.J., Jeong J.H., Lee S., Lee M.H., Yoo S.M., Lee H.S., Kang H.C., Lee J.Y., Lee W.S., … Cho Y.Y. Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. Cell. Death Dis. 2018;9(3):401. doi: 10.1038/s41419-018-0433-0Lee C.J., Moon S.J., Jeong J.H., Lee S., Lee M.H., Yoo S.M., Lee H.S., Kang H.C., Lee J.Y., Lee W.S., … Cho Y.Y. Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. Cell. Death Dis. 2018;9(3):401. doi: 10.1038/s41419-018-0433-0Zhang Z., Xu W., Zhang Z., Chen X., Jin H., Jiang N., Xu H. The bone-protective benefits of kaempferol combined with metformin by regulation of osteogenesis-angiogenesis coupling in OVX rats. Biomed. Pharmacother. 2024;173:116364. doi: 10.1016/j.biopha.2024.116364Zhang Z., Xu W., Zhang Z., Chen X., Jin H., Jiang N., Xu H. The bone-protective benefits of kaempferol combined with metformin by regulation of osteogenesis-angiogenesis coupling in OVX rats. Biomed. Pharmacother. 2024;173:116364. doi: 10.1016/j.biopha.2024.116364Kelepouri D., Mavropoulos A., Bogdanos D.P., Sakkas L.I. The role of flavonoids in inhibitory Th17 responses in inflammatory arthritis. J. Immunol. Res. 2018;2018:9324357. doi: 10.1155/2018/9324357Kelepouri D., Mavropoulos A., Bogdanos D.P., Sakkas L.I. The role of flavonoids in inhibitory Th17 responses in inflammatory arthritis. J. Immunol. Res. 2018;2018:9324357. doi: 10.1155/2018/9324357Huang Z., Cheng C., Cao B., Wang J., Wei H., Liu X., Han Y., Yang S., Wang X. Icariin protects against glucocorticoid-induced osteonecrosis of the femoral head of rats. Cell. Physiol. Biochem. 2018;47(2):694–706. doi: 10.1159/000490023Huang Z., Cheng C., Cao B., Wang J., Wei H., Liu X., Han Y., Yang S., Wang X. Icariin protects against glucocorticoid-induced osteonecrosis of the femoral head of rats. Cell. Physiol. Biochem. 2018;47(2):694–706. doi: 10.1159/000490023Xu H., Zhou S., Qu R., Yang Y., Gong Y., Hong Y., Jin A., Huang X., Dai Q., Jiang L. Icariin prevents oestrogen deficiency-induced alveolar bone loss through promoting osteogenesis via STAT3. Cell. Prolif. 2020;53(2):e12743. doi: 10.1111/cpr.12743Xu H., Zhou S., Qu R., Yang Y., Gong Y., Hong Y., Jin A., Huang X., Dai Q., Jiang L. Icariin prevents oestrogen deficiency-induced alveolar bone loss through promoting osteogenesis via STAT3. Cell. Prolif. 2020;53(2):e12743. doi: 10.1111/cpr.12743Xu Q., Chen G., Liu X., Dai M., Zhang B. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-kappa B and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 2019;508(3):902–906. doi: 10.1016/j.bbrc.2018.11.201Xu Q., Chen G., Liu X., Dai M., Zhang B. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-kappa B and MAPK signaling pathways. Biochem. Biophys. Res. Commun. 2019;508(3):902–906. doi: 10.1016/j.bbrc.2018.11.201Chi L., Gao W., Shu X., Lu X. A natural flavonoid glucoside, icariin, regulates Th17 and alleviates rheumatoid arthritis in a murine model. Mediators Inflamm. 2014;2014:392062. doi: 10.1155/2014/392062Chi L., Gao W., Shu X., Lu X. A natural flavonoid glucoside, icariin, regulates Th17 and alleviates rheumatoid arthritis in a murine model. Mediators Inflamm. 2014;2014:392062. doi: 10.1155/2014/392062Sun P., Liu Y., Deng X., Yu C., Dai N., Yuan X., Chen L., Yu S., Si W., Wang X., … Pang H. An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis. Phytomedicine. 2013;20(11):975–979. doi: 10.1016/j.phymed.2013.04.019Sun P., Liu Y., Deng X., Yu C., Dai N., Yuan X., Chen L., Yu S., Si W., Wang X., … Pang H. An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis. Phytomedicine. 2013;20(11):975–979. doi: 10.1016/j.phymed.2013.04.019Xue L., Jiang Y., Han T., Zhang N., Qin L., Xin H., Zhang Q. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maxim. J. Ethnopharmacol. 2016;192:370–381. doi: 10.1016/j.jep.2016.07.037Xue L., Jiang Y., Han T., Zhang N., Qin L., Xin H., Zhang Q. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu maxim. J. Ethnopharmacol. 2016;192:370–381. doi: 10.1016/j.jep.2016.07.037Hughes S.D., Ketheesan N., Haleagrahara N. The therapeutic potential of plant flavonoids on rheumatoid arthritis. Crit. Rev. Food Sci. Nutr. 2017;57(17):3601–3613. doi: 10.1080/10408398.2016.1246413Hughes S.D., Ketheesan N., Haleagrahara N. The therapeutic potential of plant flavonoids on rheumatoid arthritis. Crit. Rev. Food Sci. Nutr. 2017;57(17):3601–3613. doi: 10.1080/10408398.2016.1246413Zhang X., Zhou C., Zha X., Xu Z., Li L., Liu Y., Xu L., Cui L., Xu D., Zhu B. Apigenin promotes osteogenic differentiation of human mesenchymal stem cells through JNK and P38 MAPK pathways. Mol. Cell. Biochem. 2015;407(1-2):41–50. doi: 10.1007/s11010-015-2452-9Zhang X., Zhou C., Zha X., Xu Z., Li L., Liu Y., Xu L., Cui L., Xu D., Zhu B. Apigenin promotes osteogenic differentiation of human mesenchymal stem cells through JNK and P38 MAPK pathways. Mol. Cell. Biochem. 2015;407(1-2):41–50. doi: 10.1007/s11010-015-2452-9Lorusso F., Scarano A., Fulle S., Valbonetti L., Mancinelli R., di Filippo E.S. Effectiveness of apigenin, resveratrol, and curcumin as adjuvant nutraceuticals for calvarial bone defect healing: an in vitro and histological study on rats. Nutrients. 2023;15(5):1235. doi: 10.3390/nu15051235Lorusso F., Scarano A., Fulle S., Valbonetti L., Mancinelli R., di Filippo E.S. Effectiveness of apigenin, resveratrol, and curcumin as adjuvant nutraceuticals for calvarial bone defect healing: an in vitro and histological study on rats. Nutrients. 2023;15(5):1235. doi: 10.3390/nu15051235Ali D., Okla M., Abuelreich S., Vishnabalaji R., Ditzel N., Hamam R., Kowal J.M., Sayed A., Aldahmash A., Alajez N.M., Kassem M. Apigenin and rutaecarpine reduce the burden of cellular senescence in bone morrow stromal stem cells. Front. Endocrinol. (Lausanne). 2024;15:1360054. doi: 10.3389/fendo.2024.1360054Ali D., Okla M., Abuelreich S., Vishnabalaji R., Ditzel N., Hamam R., Kowal J.M., Sayed A., Aldahmash A., Alajez N.M., Kassem M. Apigenin and rutaecarpine reduce the burden of cellular senescence in bone morrow stromal stem cells. Front. Endocrinol. (Lausanne). 2024;15:1360054. doi: 10.3389/fendo.2024.1360054d’Amico E., Pierfelice T.V., Iezzi G., di Pietro N., Lepore S., Lorusso F., Scarano A., Pandolfi A., Piattelli A., Petrini M. Apigenin promotes proliferation and mineralization human osteoblasts and up-regulates osteogenic markers. Appl. Sci. 2022;12:8510. doi: 10.3390/app12178510d’Amico E., Pierfelice T.V., Iezzi G., di Pietro N., Lepore S., Lorusso F., Scarano A., Pandolfi A., Piattelli A., Petrini M. Apigenin promotes proliferation and mineralization human osteoblasts and up-regulates osteogenic markers. Appl. Sci. 2022;12:8510. doi: 10.3390/app12178510Asadi A., Goudarzi F., Ghanadian M., Mohammadalipour A. Evaluation of the osteogenic effect of apigenin on human mesenchymal stem cells by inhibiting inflammation through modulation of NF-κB/IκBα. Res. Pharm. Sci. 2022;17(6):697–706. doi: 10.4103/1735-5362.359436Asadi A., Goudarzi F., Ghanadian M., Mohammadalipour A. Evaluation of the osteogenic effect of apigenin on human mesenchymal stem cells by inhibiting inflammation through modulation of NF-κB/IκBα. Res. Pharm. Sci. 2022;17(6):697–706. doi: 10.4103/1735-5362.359436Jung W.W. Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells. Int. J. Mol. Med. 2014;33(5):1327–1334. doi: 10.3892/ijmm.2014.1666Jung W.W. Protective effect of apigenin against oxidative stress-induced damage in osteoblastic cells. Int. J. Mol. Med. 2014;33(5):1327–1334. doi: 10.3892/ijmm.2014.1666Bandyopadhyay S., Lion J.M., Mentaverri R., Ricupero D.A., Kamel S., Romero J., Chattopadhyay N. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem. Pharmacol. 2006;72(2):184–197. doi: 10.1016/j.bcp.2006.04.018Bandyopadhyay S., Lion J.M., Mentaverri R., Ricupero D.A., Kamel S., Romero J., Chattopadhyay N. Attenuation of osteoclastogenesis and osteoclast function by apigenin. Biochem. Pharmacol. 2006;72(2):184–197. doi: 10.1016/j.bcp.2006.04.018Li Y., Yang B., Bai Y.U., Xia S., Mao M., Li X., Li N., Chen L. The roles of synovial hyperplasia, angiogenesis and osteoclastogenesis in the protective effect of apigenin in collagen-induced arthritis. Int. Immunopharmacol. 2019;73:362–369. doi: 10.1016/j.intimp.2019.05.024Li Y., Yang B., Bai Y.U., Xia S., Mao M., Li X., Li N., Chen L. The roles of synovial hyperplasia, angiogenesis and osteoclastogenesis in the protective effect of apigenin in collagen-induced arthritis. Int. Immunopharmacol. 2019;73:362–369. doi: 10.1016/j.intimp.2019.05.024Goto T., Hagiwara K., Shirai N., Yoshida K., Hagiwara H. Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology. 2015;67(2):357–362. doi: 10.1007/s10616-014-9694-3Goto T., Hagiwara K., Shirai N., Yoshida K., Hagiwara H. Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology. 2015;67(2):357–362. doi: 10.1007/s10616-014-9694-3Choi E.M. Luteolin protects osteoblastic MC3T3-E1 cells from antimycin A-induced cytototoxicity through the improved mitochondrial function and activation of PI3K/Akt/CREB. Toxicol. In Vitro. 2011;25(8):1671–1679. doi: 10.1016/j.tiv.2011.07.004Choi E.M. Luteolin protects osteoblastic MC3T3-E1 cells from antimycin A-induced cytototoxicity through the improved mitochondrial function and activation of PI3K/Akt/CREB. Toxicol. In Vitro. 2011;25(8):1671–1679. doi: 10.1016/j.tiv.2011.07.004Zheng L. Luteolin stimulates proliferation and inhibits late differentiation of primary rat calvarial osteoblast induced by high-dose dexamethasone via Sema3A/NRP1/Plexin A1. Curr. Pharm. Biotechnol. 2021;22(11):1538–1545. doi: 10.2174/1389201021666201216150442Zheng L. Luteolin stimulates proliferation and inhibits late differentiation of primary rat calvarial osteoblast induced by high-dose dexamethasone via Sema3A/NRP1/Plexin A1. Curr. Pharm. Biotechnol. 2021;22(11):1538–1545. doi: 10.2174/1389201021666201216150442Jing Z., Wang C., Yang Q., Wei X., Jin Y., Meng Q., Liu Q., Liu Z., Ma X., Liu K., Sun H., Liu M. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J. Cell. Physiol. 2019;234(4):4472–4490. doi: 10.1002/jcp.27252Jing Z., Wang C., Yang Q., Wei X., Jin Y., Meng Q., Liu Q., Liu Z., Ma X., Liu K., Sun H., Liu M. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J. Cell. Physiol. 2019;234(4):4472–4490. doi: 10.1002/jcp.27252Lee J.W., Ahn J.Y., Hasegawa S.I., Cha B.Y., Yonezawa T., Nagai K., Seo H.J., Jeon W.B., Wao J.T. Inhibitory effect of luteolin on osteoclast differentiation and function. Cytotechnology. 2009;61(3):125–134. doi: 10.1007/s10616-010-9253-5Lee J.W., Ahn J.Y., Hasegawa S.I., Cha B.Y., Yonezawa T., Nagai K., Seo H.J., Jeon W.B., Wao J.T. Inhibitory effect of luteolin on osteoclast differentiation and function. Cytotechnology. 2009;61(3):125–134. doi: 10.1007/s10616-010-9253-5Chai S., Yang Y., Wei L., Cao Y., Ma J., Zheng X., Teng J., Qin N. Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling. Phytomedicine. 2024;128:155516. doi: 10.1016/j.phymed.2024.155516Chai S., Yang Y., Wei L., Cao Y., Ma J., Zheng X., Teng J., Qin N. Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling. Phytomedicine. 2024;128:155516. doi: 10.1016/j.phymed.2024.155516Song F., Wei C., Zhou L., Qin A., Yang M., Tickner J., Huang Y., Zhao J., Xu J. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. J. Cell. Physiol. 2018;233(2):1723–1735. doi: 10.1002/jcp.26084Song F., Wei C., Zhou L., Qin A., Yang M., Tickner J., Huang Y., Zhao J., Xu J. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. J. Cell. Physiol. 2018;233(2):1723–1735. doi: 10.1002/jcp.26084Kim J.M., Lee S.U., Kim Y.S., Min Y.K., Kim S.H. Baicalein stimulates osteoblast differentiation via coordinating activation MAP kinases and transcription factors. J. Cell. Biochem. 2008;104(5):1906–1917. doi: 10.1002/jcb.21760Kim J.M., Lee S.U., Kim Y.S., Min Y.K., Kim S.H. Baicalein stimulates osteoblast differentiation via coordinating activation MAP kinases and transcription factors. J. Cell. Biochem. 2008;104(5):1906–1917. doi: 10.1002/jcb.21760Li S., Tang J., Chen J., Zhang P., Wang T., Chen T., Yan B., Huang B., Wang L., Huang M., Zhang Z., Jin D. Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Des. Des. Devel. Ther. 2015;9:5169–5183. doi: 10.2147/DDDT.S81578Li S., Tang J., Chen J., Zhang P., Wang T., Chen T., Yan B., Huang B., Wang L., Huang M., Zhang Z., Jin D. Regulation of bone formation by baicalein via the mTORC1 pathway. Drug Des. Des. Devel. Ther. 2015;9:5169–5183. doi: 10.2147/DDDT.S81578Wang Q., Shi D., Geng Y., Huang Q., Xiang L. Baicalin augments the differentiation of osteoblasts via enhancement of microRNA-217. Mol. Cell. Biochem. 2020;463(1-2):91–100. doi: 10.1007/s11010-019-03632-6Wang Q., Shi D., Geng Y., Huang Q., Xiang L. Baicalin augments the differentiation of osteoblasts via enhancement of microRNA-217. Mol. Cell. Biochem. 2020;463(1-2):91–100. doi: 10.1007/s11010-019-03632-6Kim M.H., Ryu S.Y., Bae M.A., Choi J.S., Min Y.K., Kim S.H. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem. Toxicol. 2008;46(11):3375–3382. doi: 10.1016/j.fct.2008.08.016Kim M.H., Ryu S.Y., Bae M.A., Choi J.S., Min Y.K., Kim S.H. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem. Toxicol. 2008;46(11):3375–3382. doi: 10.1016/j.fct.2008.08.016Cai P., Lu Y., Yin Z., Wang X., Zhou X., Li Z. Baicalein ameliorates osteoporosis via AKT/FOXO1 signaling. Aging (Albany NY). 2021;13(13):17370–17379. doi: 10.18632/aging.203227Cai P., Lu Y., Yin Z., Wang X., Zhou X., Li Z. Baicalein ameliorates osteoporosis via AKT/FOXO1 signaling. Aging (Albany NY). 2021;13(13):17370–17379. doi: 10.18632/aging.203227Saul D., Weber M., Zimmermann M.H., Kosinsky R.L., Hoffman D.B., Menger B., Taudien S., Lehmann W., Komrakova M., Sehmisch S. Effect of the lioxygenase inhibitor baicalein on bone tissue and bone healing in ovariectomized rats. Nutr. Metab. (Lond). 2019;16:4. doi: 10.1186/s12986-018-0327-2Saul D., Weber M., Zimmermann M.H., Kosinsky R.L., Hoffman D.B., Menger B., Taudien S., Lehmann W., Komrakova M., Sehmisch S. Effect of the lioxygenase inhibitor baicalein on bone tissue and bone healing in ovariectomized rats. Nutr. Metab. (Lond). 2019;16:4. doi: 10.1186/s12986-018-0327-2Li Y., Wang X. Chrysin attenuates high glucose-induced BMSc dysfunction via the activation of the PI3K/AKT/Nrf2 signaling pathway. Drug Des. Devel. Ther. 2022;16:165–182. doi: 10.2147/DDDT.S335024Li Y., Wang X. Chrysin attenuates high glucose-induced BMSc dysfunction via the activation of the PI3K/AKT/Nrf2 signaling pathway. Drug Des. Devel. Ther. 2022;16:165–182. doi: 10.2147/DDDT.S335024Oršolić N., Nemrava J., Jeleč Ž., Kukolj M., Odeh D., Jakopović B., Jembrek M.J., Bagatin T., Fureš R., Bagatin D. Antioxidative and anti-inflammatory activities of chrysin and naringenin in a drug-induced bone loss model in rats. Int. J. Mol. Sci. 2022;23(5):2872. doi: 10.3390/ijms23052872Oršolić N., Nemrava J., Jeleč Ž., Kukolj M., Odeh D., Jakopović B., Jembrek M.J., Bagatin T., Fureš R., Bagatin D. Antioxidative and anti-inflammatory activities of chrysin and naringenin in a drug-induced bone loss model in rats. Int. J. Mol. Sci. 2022;23(5):2872. doi: 10.3390/ijms23052872Wu Z., Li C., Chen Y., Liu Q., Li N., He X., Li W., Shen R., Li L., Wei C., … Xu F. Chrysin protects against titanium particle-induced osteolysis by attenuating osteoclast formation and function by inhibiting NF-κB and MAPK signaling. Front. Pharmacol. 2022;13:793087. doi: 10.3389/fphar.2022.793087Wu Z., Li C., Chen Y., Liu Q., Li N., He X., Li W., Shen R., Li L., Wei C., … Xu F. Chrysin protects against titanium particle-induced osteolysis by attenuating osteoclast formation and function by inhibiting NF-κB and MAPK signaling. Front. Pharmacol. 2022;13:793087. doi: 10.3389/fphar.2022.793087Ortiz A.C., Fideles S.O.M., Reis C.H.B., Bellini M.Z., Pereira E.S.B.M., Pilon J.P.G., de Marchi M.A., Detregiachi C.R.P., Flato U.A.P., de Moraes Triazzi B.F., … Buchaim R.L. Therapeutic effects of citrus flavonoids neohesperidin, hesperidin and its aglycone, hesperetin on bone health. Biomolecules. 2022;12(5):626. doi: 10.3390/biom12050626Ortiz A.C., Fideles S.O.M., Reis C.H.B., Bellini M.Z., Pereira E.S.B.M., Pilon J.P.G., de Marchi M.A., Detregiachi C.R.P., Flato U.A.P., de Moraes Triazzi B.F., … Buchaim R.L. Therapeutic effects of citrus flavonoids neohesperidin, hesperidin and its aglycone, hesperetin on bone health. Biomolecules. 2022;12(5):626. doi: 10.3390/biom12050626Hong W., Zhang W. Hesperidin promotes differentiation of alveolar osteoblasts via Wnt/β-catenin signaling pathway. J. Recept. Signal. Transduct. Res. 2020;40(5):442–448. doi: 10.1080/10799893.2020.1752718Hong W., Zhang W. Hesperidin promotes differentiation of alveolar osteoblasts via Wnt/β-catenin signaling pathway. J. Recept. Signal. Transduct. Res. 2020;40(5):442–448. doi: 10.1080/10799893.2020.1752718Miguez P.A., Tuin S.A., Robinson A.G., Belcher J., Longwattanapisan P., Perley K., de Paiva Gonçalves, Hanifi A., Pleshko N., Barton E.R. Hesperidin promotes osteogenesis and modulates collagen matrix organization and mineralization in vitro and in vivo. Int. J. Mol. Sci. 2021;22(6):3223. doi: 10.3390/ijms22063223Miguez P.A., Tuin S.A., Robinson A.G., Belcher J., Longwattanapisan P., Perley K., de Paiva Gonçalves, Hanifi A., Pleshko N., Barton E.R. Hesperidin promotes osteogenesis and modulates collagen matrix organization and mineralization in vitro and in vivo. Int. J. Mol. Sci. 2021;22(6):3223. doi: 10.3390/ijms22063223Liu L., Zheng J., Yang Y.Z., Ni L., Chen H., Yu D. Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway. Med. Mol. Morphol. 2021;54(1):1–7. doi: 10.1007/s00795-020-00251-9Liu L., Zheng J., Yang Y.Z., Ni L., Chen H., Yu D. Hesperetin alleviated glucocorticoid-induced inhibition of osteogenic differentiation of BMSCs through regulating the ERK signaling pathway. Med. Mol. Morphol. 2021;54(1):1–7. doi: 10.1007/s00795-020-00251-9Hu H.Y., Zhang Z.Z., Jiang X.Y., Duan T.H., Feng W., Wang X.G. Hesperidin anti-osteoporosis by regulating estrogen signaling pathways. Molecules. 2023;28(19):6987. doi: 10.3390/molecules28196987Hu H.Y., Zhang Z.Z., Jiang X.Y., Duan T.H., Feng W., Wang X.G. Hesperidin anti-osteoporosis by regulating estrogen signaling pathways. Molecules. 2023;28(19):6987. doi: 10.3390/molecules28196987Zhang M., Chen D., Zeng N., Liu Z., Chen X., Xiao H., Xiao L., Liu Z., Dong Y., Zheng J. Hesperidin ameliorates dexamethasone-induced osteoporosis by inhibiting p53. Front. Cell. Dev. Biol. 2022;10:820922. doi: 10.3389/fcell.2022.820922Zhang M., Chen D., Zeng N., Liu Z., Chen X., Xiao H., Xiao L., Liu Z., Dong Y., Zheng J. Hesperidin ameliorates dexamethasone-induced osteoporosis by inhibiting p53. Front. Cell. Dev. Biol. 2022;10:820922. doi: 10.3389/fcell.2022.820922Uehara M. Prevention of osteoporosis by foods and dietary supplements. Hesperidin and bone metabolism. Clin. Calcium. 2006;16(10):1669–1676.Uehara M. Prevention of osteoporosis by foods and dietary supplements. Hesperidin and bone metabolism. Clin. Calcium. 2006;16(10):1669–1676.Shehata A.S., Amer M.G., Abd El-Haleem M.R., Karam R.A. The ability of hesperidin compared to that of insulin for preventing osteoporosis induced by type I diabetes in young male albino rats: a histological and biochemical study. Exp. Toxicol. Pathol. 2017;69(4):203–212. doi: 10.1016/j.etp.2017.01.008Shehata A.S., Amer M.G., Abd El-Haleem M.R., Karam R.A. The ability of hesperidin compared to that of insulin for preventing osteoporosis induced by type I diabetes in young male albino rats: a histological and biochemical study. Exp. Toxicol. Pathol. 2017;69(4):203–212. doi: 10.1016/j.etp.2017.01.008Aihaiti Y., Cai Y.S., Tuerhong X., Yang Y.N., Ma Y., Zheng H.S., Xu K., Xu P. Therapeutic effects of naringin in rheumatoid asthritis: network pharmacology and experimental validation. Front. Pharmacol. 2021;12:672054. doi: 10.3389/fphar.2021.672054Aihaiti Y., Cai Y.S., Tuerhong X., Yang Y.N., Ma Y., Zheng H.S., Xu K., Xu P. Therapeutic effects of naringin in rheumatoid asthritis: network pharmacology and experimental validation. Front. Pharmacol. 2021;12:672054. doi: 10.3389/fphar.2021.672054Yu X., Zhang P., Tang K., Shen H., Chen H., Zhang Z., Zhao W., Shang Q., Zhu G., Tan R., … Zhou B. Network pharmacology integrated with molecular docking explores the mechanisms of naringin against osteoporotic fracture by regulating oxidative stress. Evid. Based Complement. Alternat. Med. 2021;2021:6421122. doi: 10.1155/2021/6421122Yu X., Zhang P., Tang K., Shen H., Chen H., Zhang Z., Zhao W., Shang Q., Zhu G., Tan R., … Zhou B. Network pharmacology integrated with molecular docking explores the mechanisms of naringin against osteoporotic fracture by regulating oxidative stress. Evid. Based Complement. Alternat. Med. 2021;2021:6421122. doi: 10.1155/2021/6421122Nor Muhamad M.L., Ekeuku S.O., Wong S.K., Chin K.Y. A scoping review of the skeletal effects of naringenin. Nutrients. 2022;14(22):4851. doi: 10.3390/nu14224851Nor Muhamad M.L., Ekeuku S.O., Wong S.K., Chin K.Y. A scoping review of the skeletal effects of naringenin. Nutrients. 2022;14(22):4851. doi: 10.3390/nu14224851Gan J., Deng X., Le Y., Lai J., Liao A. The development of naringin for use against bone and cartilage disorders. Molecules. 2023;28(9):3716. doi: 10.3390/molecules28093716Gan J., Deng X., Le Y., Lai J., Liao A. The development of naringin for use against bone and cartilage disorders. Molecules. 2023;28(9):3716. doi: 10.3390/molecules28093716Ang E.S.M., Yang X., Chen H., Liu Q., Zheng M.H., Xu J. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation. FEBS Lett. 2011;585(17):2755–2762. doi: 10.1016/j.febslet.2011.07.046Ang E.S.M., Yang X., Chen H., Liu Q., Zheng M.H., Xu J. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-κB and ERK activation. FEBS Lett. 2011;585(17):2755–2762. doi: 10.1016/j.febslet.2011.07.046Wang W., Li M., Luo M., Shen M., Xu C., Xu G., Chen Y., Xia L. Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4. J. Cell. Biochem. 2018;119(2):2084–2093. doi: 10.1002/jcb.26370Wang W., Li M., Luo M., Shen M., Xu C., Xu G., Chen Y., Xia L. Naringenin inhibits osteoclastogenesis through modulation of helper T cells-secreted IL-4. J. Cell. Biochem. 2018;119(2):2084–2093. doi: 10.1002/jcb.26370Wang W., Wu C., Tian B., Liu X., Zhai Z., Qu X., Jiang C., Ouyang Z., Mao Y., Tang T., Qin A., Zhu Z. The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis. Int. J. Mol. Sci. 2014;15(12):21913–21934. doi: 10.3390/ijms151221913Wang W., Wu C., Tian B., Liu X., Zhai Z., Qu X., Jiang C., Ouyang Z., Mao Y., Tang T., Qin A., Zhu Z. The inhibition of RANKL-induced osteoclastogenesis through the suppression of p38 signaling pathway by naringenin and attenuation of titanium-particle-induced osteolysis. Int. J. Mol. Sci. 2014;15(12):21913–21934. doi: 10.3390/ijms151221913Oršolić N., Goluža E., Dikić D., Lisičić D., Sašilo K., Rođ E., Jeleć Ž., Lazarus M.V., Orct T. Role of flavonoids on oxidative stress and mineral contents in the retinoic acid-induced bone loss model of rat. Eur. J. Nutr. 2014;53(5):1217–1227. doi: 10.1007/s00394-013-0622-7Oršolić N., Goluža E., Dikić D., Lisičić D., Sašilo K., Rođ E., Jeleć Ž., Lazarus M.V., Orct T. Role of flavonoids on oxidative stress and mineral contents in the retinoic acid-induced bone loss model of rat. Eur. J. Nutr. 2014;53(5):1217–1227. doi: 10.1007/s00394-013-0622-7Bussmann A.J.C., Borghi S.M., Zaninelli T.H., Dos Santos T.S., Guazelli C.F.S., Fattori V., Domiciano T.P., Pinho-Ribeiro F.A., Ruiz-Miyazawa K.W., Casella A.M.B., … Verri W.A. The citrus flavanone naringenin attenuates zymosan-induced mouse joint inflammation: induction of Nrf2 expression in recruited CD45 hematopoietic cells. Inflammopharmacology. 2019;27(6):1229–1242. doi: 10.1007/s10787-018-00561-6Bussmann A.J.C., Borghi S.M., Zaninelli T.H., Dos Santos T.S., Guazelli C.F.S., Fattori V., Domiciano T.P., Pinho-Ribeiro F.A., Ruiz-Miyazawa K.W., Casella A.M.B., … Verri W.A. The citrus flavanone naringenin attenuates zymosan-induced mouse joint inflammation: induction of Nrf2 expression in recruited CD45 hematopoietic cells. Inflammopharmacology. 2019;27(6):1229–1242. doi: 10.1007/s10787-018-00561-6Jagetia G.C., Venkatesha V.A., Reddy T.K. Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. Mutagenesis. 2003;18(4):337–343. doi: 10.1093/mutage/geg001Jagetia G.C., Venkatesha V.A., Reddy T.K. Naringin, a citrus flavonone, protects against radiation-induced chromosome damage in mouse bone marrow. Mutagenesis. 2003;18(4):337–343. doi: 10.1093/mutage/geg001Swarnkar G., Sharan K., Siddiqui J.A., Mishra J.S., Khan K., Gupta V., Rawat R., Maurya R., Dwivedi A.K., Sanyal S., Chattopadhyay N. A naturally occurring derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br. J. Pharmacol. 2012;165(5):1526–1542. doi: 10.1111/j.1476-5381.2011.01637.xSwarnkar G., Sharan K., Siddiqui J.A., Mishra J.S., Khan K., Gupta V., Rawat R., Maurya R., Dwivedi A.K., Sanyal S., Chattopadhyay N. A naturally occurring derivative exerts potent bone anabolic effects by mimicking oestrogen action on osteoblasts. Br. J. Pharmacol. 2012;165(5):1526–1542. doi: 10.1111/j.1476-5381.2011.01637.xXie X., Fu J., Gou W., Qin Y., Wang D., Huang Z., Wang L., Li X. Potential mechanism of tea for treating osteoporosis, osteoarthritis, and rheumatoid arthritis. Front. Med. (Lausanne). 2024;11:1289777. doi: 10.3389/fmed.2024.1289777Xie X., Fu J., Gou W., Qin Y., Wang D., Huang Z., Wang L., Li X. Potential mechanism of tea for treating osteoporosis, osteoarthritis, and rheumatoid arthritis. Front. Med. (Lausanne). 2024;11:1289777. doi: 10.3389/fmed.2024.1289777Kaida K., Honda Y., Hashimoto Y., Tanaka M., Baba S. Application of green tea catechin for inducing the osteogenic differentiation of human differentiated fat cells in vitro. Int. J. Mol. Sci. 2015;16(12):27988–28000. doi: 10.3390/ijms161226081Kaida K., Honda Y., Hashimoto Y., Tanaka M., Baba S. Application of green tea catechin for inducing the osteogenic differentiation of human differentiated fat cells in vitro. Int. J. Mol. Sci. 2015;16(12):27988–28000. doi: 10.3390/ijms161226081Sakai G., Otsuka T., Fujita K., Kainuma S., Kuroyanagi G., Kawabata T., Matsushima-Nishiwaki R., Kozawa O., Tokuda H. Amplification by (-)-epigallocatechin gallate of prostaglandin F2α-stimulated synthesis of osteoprotegerin in osteoblasts. Mol. Med. Rep. 2017;16(5):6376–6381. doi: 10.3892/mmr.2017.7354Sakai G., Otsuka T., Fujita K., Kainuma S., Kuroyanagi G., Kawabata T., Matsushima-Nishiwaki R., Kozawa O., Tokuda H. Amplification by (-)-epigallocatechin gallate of prostaglandin F2α-stimulated synthesis of osteoprotegerin in osteoblasts. Mol. Med. Rep. 2017;16(5):6376–6381. doi: 10.3892/mmr.2017.7354Wong K.C., Cao S., Dong X., Law M.C., Chan T.H., Wong M.S. (-)-Epiafzelechin protects against ovariectomy-induced bone loss in adult mice and modulate osteoblastic and osteoclastic functions in vitro. Nutrients. 2017;9(5):530. doi: 10.3390/nu9050530Wong K.C., Cao S., Dong X., Law M.C., Chan T.H., Wong M.S. (-)-Epiafzelechin protects against ovariectomy-induced bone loss in adult mice and modulate osteoblastic and osteoclastic functions in vitro. Nutrients. 2017;9(5):530. doi: 10.3390/nu9050530Morinobu A., Biao W., Tanaka S., Horiuchi M., Jun L., Tsuji G., Sakai Y., Kurosaka M., Kumagai S. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum. 2008;58(7):2012–2018. doi: 10.1002/art.23594Morinobu A., Biao W., Tanaka S., Horiuchi M., Jun L., Tsuji G., Sakai Y., Kurosaka M., Kumagai S. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum. 2008;58(7):2012–2018. doi: 10.1002/art.23594Park K.H., Gu D.R., So H.S., Kim K.J., Lee S.H. Dual role of cyanide-3-glycoside on the differentiation of bone cells. J. Dent. Res. 2015;94(12):1676–1683. doi: 10.1177/0022034515604620Park K.H., Gu D.R., So H.S., Kim K.J., Lee S.H. Dual role of cyanide-3-glycoside on the differentiation of bone cells. J. Dent. Res. 2015;94(12):1676–1683. doi: 10.1177/0022034515604620Saulite L., Jekabsons K., Klavins M., Muceniece R., Riekstina U. Effects of malvidin, cyaniding and delphinidin on human adipose mesenchymal stem cell differentiation into adipocytes, chondrocytes and osteocytes. Phytomedicine. 2019;53:86–95. doi: 10.1016/j.phymed.2018.09.029Saulite L., Jekabsons K., Klavins M., Muceniece R., Riekstina U. Effects of malvidin, cyaniding and delphinidin on human adipose mesenchymal stem cell differentiation into adipocytes, chondrocytes and osteocytes. Phytomedicine. 2019;53:86–95. doi: 10.1016/j.phymed.2018.09.029Moriwaki S., Suzuki K., Muramatsu M., Nomura A., Inoue F., Into T., Yoshiko Y., Niida S. Delphinidin, one of the major anthocyanidins, prevents bone loss through the inhibition of excessive osteoclastogenesis in osteoposis model mice. PLoS One. 2014;9(5):e97177. doi: 10.1371/journal.pone.0097177Moriwaki S., Suzuki K., Muramatsu M., Nomura A., Inoue F., Into T., Yoshiko Y., Niida S. Delphinidin, one of the major anthocyanidins, prevents bone loss through the inhibition of excessive osteoclastogenesis in osteoposis model mice. PLoS One. 2014;9(5):e97177. doi: 10.1371/journal.pone.0097177Nagaoka M., Maeda T., Moriwaki S., Nomura A., Kato Y., Niida S., Kruger M.C., Suzuki K. Petunidin, a B-ring 5’-O-methylated derivative of delphinidin, stimulates osteoblastogenesis and reduces sRANKL-induced bone loss. Int. J. Mol. Sci. 2019;20(11):2795. doi: 10.3390/ijms20112795Nagaoka M., Maeda T., Moriwaki S., Nomura A., Kato Y., Niida S., Kruger M.C., Suzuki K. Petunidin, a B-ring 5’-O-methylated derivative of delphinidin, stimulates osteoblastogenesis and reduces sRANKL-induced bone loss. Int. J. Mol. Sci. 2019;20(11):2795. doi: 10.3390/ijms20112795Chen G.D., Liang S.J., Huang L., Yu H.R., Wu Y.L., Wei Q.Z., Zhang Z.Q. Association of dietary anthocyanidins intake with bone health in children: a cross-sectional study. Calif. Tissue Int. 2023;113(4):393–402. doi: 10.1007/s00223-023-01128-6Chen G.D., Liang S.J., Huang L., Yu H.R., Wu Y.L., Wei Q.Z., Zhang Z.Q. Association of dietary anthocyanidins intake with bone health in children: a cross-sectional study. Calif. Tissue Int. 2023;113(4):393–402. doi: 10.1007/s00223-023-01128-6Филиппова О.В. Фитоэстрогены: перспективы применения. Эффектив. фармакотерапия. 2020;16(22):30–36. doi: 10.33978/2307-3586-2020-16-22-30-36Filippova O.V. Phytoestrogens: prospects of use. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2020;16(22):30–36. [In Russian]. doi: 10.33978/2307-3586-2020-16-22-30-36Mohapatra S., Kumar P.A., Aggarwal A., Iqubal A., Mirza M.A., Iqbal Z. Phytotherapeutic approach for conquering menopausal syndrome and osteoporosis. Phytother. Res. 2024;38(6):2728–2763. doi: 10.1002/ptr.8172Mohapatra S., Kumar P.A., Aggarwal A., Iqubal A., Mirza M.A., Iqbal Z. Phytotherapeutic approach for conquering menopausal syndrome and osteoporosis. Phytother. Res. 2024;38(6):2728–2763. doi: 10.1002/ptr.8172Liao M.H., Tai Y.T., Cherng Y.G., Liu S.H., Chang Y.A., Lin P.I., Chen R.M. Genistein induces oestrogen receptor-α gene expression in osteoblasts through the activation of mitogen-activated protein kinase/NF-κB/activator protein-1 and promotes cell mineralization. Br. J. Nutr. 2014;111(1):55–63. doi: 10.1017/S0007114513002043Liao M.H., Tai Y.T., Cherng Y.G., Liu S.H., Chang Y.A., Lin P.I., Chen R.M. Genistein induces oestrogen receptor-α gene expression in osteoblasts through the activation of mitogen-activated protein kinase/NF-κB/activator protein-1 and promotes cell mineralization. Br. J. Nutr. 2014;111(1):55–63. doi: 10.1017/S0007114513002043Kim M., Lim J., Lee J.H., Lee K.M., Kim S., Park K.W., Nho C.W., Cho Y.C. Understanding the functional role of genistein in the bone differentiation in mouse osteoblastic cell line MC3T3-E1 by RNA-Seq analysis. Sci. Rep. 2018;8(1):1–12. doi: 10.1038/s41598-018-21601-9Kim M., Lim J., Lee J.H., Lee K.M., Kim S., Park K.W., Nho C.W., Cho Y.C. Understanding the functional role of genistein in the bone differentiation in mouse osteoblastic cell line MC3T3-E1 by RNA-Seq analysis. Sci. Rep. 2018;8(1):1–12. doi: 10.1038/s41598-018-21601-9Cepeda S.B., Sandoval M.J., Crescitelli M.C., Rauschemberger M.B., Massheimer V.Z. The isoflavone genistein enhances osteoblastogenesis: signaling pathways involved. J. Physiol. Biochem. 2020;76(1):99–110. doi: 10.1007/s13105-019-00722-3Cepeda S.B., Sandoval M.J., Crescitelli M.C., Rauschemberger M.B., Massheimer V.Z. The isoflavone genistein enhances osteoblastogenesis: signaling pathways involved. J. Physiol. Biochem. 2020;76(1):99–110. doi: 10.1007/s13105-019-00722-3Chakraborty D., Gupta K., Biswas S. A mechanistic insights of phytoestrogens used for rheumatoid arthritis : an evidence-based review. Biomed. Pharmacother. 2021;133:111039. doi: 10.1016/j.biopha.2020.111039Chakraborty D., Gupta K., Biswas S. A mechanistic insights of phytoestrogens used for rheumatoid arthritis : an evidence-based review. Biomed. Pharmacother. 2021;133:111039. doi: 10.1016/j.biopha.2020.111039Filipović B., Sošić-JurjevićB., Ajdžanović V., Živanović J., Manojlović-Stojanovski M., Nestorović N., Ristić N., Trifunović S., Milošević V. The phytoestrogen genistein prevents trabecular bone loss and affects thyroid follicular cells in a male rat model of osteoporosis. J. Anat. 2018;233(2):204–212. doi: 10.1111/joa.12828Filipović B., Sošić-JurjevićB., Ajdžanović V., Živanović J., Manojlović-Stojanovski M., Nestorović N., Ristić N., Trifunović S., Milošević V. The phytoestrogen genistein prevents trabecular bone loss and affects thyroid follicular cells in a male rat model of osteoporosis. J. Anat. 2018;233(2):204–212. doi: 10.1111/joa.12828Karieb S., Fox S.W. Phytoestrogens directly inhibit TNF-α-induced bone resorption in RAW264.7 cells by suppressing c-fos-induced NFATc1 expression. J. Cell. Biochem. 2011;112(2):476–487. doi: 10.1002/jcb.22935Karieb S., Fox S.W. Phytoestrogens directly inhibit TNF-α-induced bone resorption in RAW264.7 cells by suppressing c-fos-induced NFATc1 expression. J. Cell. Biochem. 2011;112(2):476–487. doi: 10.1002/jcb.22935Park K., Ju W.C., Jeo J.H., Kim J.Y., Seo H.S., Uchida Y., Cho Y. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation. Int. J. Mol. Med. 2014;33(1):178–184. doi: 10.3892/ijmm.2013.1557Park K., Ju W.C., Jeo J.H., Kim J.Y., Seo H.S., Uchida Y., Cho Y. Increased OPG/RANKL ratio in the conditioned medium of soybean-treated osteoblasts suppresses RANKL-induced osteoclast differentiation. Int. J. Mol. Med. 2014;33(1):178–184. doi: 10.3892/ijmm.2013.1557de Wilde A., Lieberherr M., Colin C., Pointillart A. A low dose of daidzein acts as an Erβ-selective agonist in trabecular osteoblasts of young female piglets. J. Cell. Physiol. 2004;200(2):253–262. doi: 10,1002/jcp.20008de Wilde A., Lieberherr M., Colin C., Pointillart A. A low dose of daidzein acts as an Erβ-selective agonist in trabecular osteoblasts of young female piglets. J. Cell. Physiol. 2004;200(2):253–262. doi: 10,1002/jcp.20008Huh J.E., Lee W.I., Kang J.W., Nam D., Choi D.Y., Park D.S., Lee S.H., Lee J.D. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway. J. Nat. Prod. 2014;77(11):2423–2431. doi: 10.1021/np500417dHuh J.E., Lee W.I., Kang J.W., Nam D., Choi D.Y., Park D.S., Lee S.H., Lee J.D. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway. J. Nat. Prod. 2014;77(11):2423–2431. doi: 10.1021/np500417dZverev Ya.F., Rykunova A.Ya. Modern nanocarriers as a factor in increasing the bioavailability and pharmacological activity of flavonoids. Appl. Biochem. Microbiol. 2022;58(9):1002–1020. doi: 10.1134/s0003683822090149Zverev Ya.F., Rykunova A.Ya. Modern nanocarriers as a factor in increasing the bioavailability and pharmacological activity of flavonoids. Appl. Biochem. Microbiol. 2022;58(9):1002–1020. doi: 10.1134/s0003683822090149

The authors declare that there are no conflicts of interest present.